New Alzheimer’s Drug Repairs DNA Damage and Cuts Brain Inflammation

Breakthrough drug repurposed from spinal cord injury research

A team of neuroscientists has identified a compound that was originally created to treat injuries of the spinal cord and found that it also addresses two of the most damaging processes in Alzheimer’s disease: DNA damage and chronic brain inflammation. The discovery emerged from a collaborative effort between a university research laboratory and a biotech company that specializes in neuroprotective agents.

Key mechanisms targeted by the drug

The experimental medication works through several pathways that intersect with the biology of Alzheimer’s. Its primary actions include:

Enhancing the activity of cellular enzymes that repair broken DNA strands in neurons.
Reducing the release of inflammatory molecules from microglial cells, the brain’s resident immune cells.
Stabilising mitochondrial function, which helps maintain the energy supply needed for neuron survival.
Modulating protein folding processes that prevent the accumulation of toxic aggregates.

Evidence from early human safety trials

In a phase 1 study involving a small group of older adults with mild cognitive impairment, participants received a low dose of the drug for twelve weeks. Researchers reported no serious adverse events and observed modest improvements in biomarkers of DNA repair and inflammation measured in cerebrospinal fluid. The trial was registered with the National Institutes of Health clinical trials database, and the data are currently being reviewed for publication.

Potential impact on Alzheimer’s treatment landscape

Current therapeutic approaches for Alzheimer’s focus largely on reducing amyloid plaques or enhancing neurotransmitter activity. By directly repairing DNA damage and dampening neuroinflammation, the new drug offers a fundamentally different strategy that targets the disease at its root causes. If larger trials confirm these early signals, the medication could be used alongside existing treatments to slow progression more effectively.

"Addressing the underlying cellular stress that drives neuron loss may be the missing piece in our fight against Alzheimer’s," said Dr. Elena Morales, lead investigator of the study.

Steps toward wider clinical testing

Complete a phase 2 trial to evaluate efficacy in a larger cohort of patients with early stage Alzheimer’s.
Conduct a dose‑finding study to identify the optimal therapeutic window.
Submit an investigational new drug application to the U.S. Food and Drug Administration for permission to begin phase 3 trials.
Partner with academic medical centers to enroll diverse participants, ensuring results are applicable across populations.
Publish the full trial data in a peer‑reviewed journal such as Nature Neuroscience to allow independent validation.

While the path to approval will require rigorous testing, the drug’s existing safety profile in spinal cord injury patients shortens the timeline compared with entirely new compounds. Researchers are hopeful that the dual action on DNA repair and inflammation will translate into meaningful clinical benefits.

Experts from the Alzheimer's Association have praised the approach, noting that “targeting cellular resilience is a promising direction that aligns with emerging insights into disease biology.” The scientific community will be watching the upcoming trials closely, as success could reshape how neurodegenerative disorders are treated.

Continued funding, transparent data sharing, and collaboration between industry and academia will be essential to move the candidate from the laboratory to the clinic. The discovery underscores the value of drug repurposing, where existing molecules can be redirected to meet urgent unmet medical needs.